Payment overview · 2025
General Payments
$473.70
21 reported records · 11 companies
Healthcare provider profile · identity verified
Jarrell Austin Hill, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · PHILADELPHIA, PA · NPI 1629663836
Verified facts
What the public records show
CMS Open Payments records show Jarrell Austin Hill, NP received $473.70 in general payments during 2025 across 21 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $100.36 | 21.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.61 | 14.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.04 | 11.8% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $45.91 | 9.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.10 | 8.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.47 | 7.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.74 | 7.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.59 | 6.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.13 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.02 | 3.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.73 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $473.70 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.36 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.61 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.61 | 3 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $45.91 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $39.10 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.47 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.88 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.59 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 507 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 423 | 126 |
| Gabapentin | Gabapentin | 252 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 232 | 51 |
| Losartan Potassium | Losartan Potassium | 173 | 62 |
| Metformin Hcl | Metformin Hcl | 167 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 49 |
| Famotidine | Famotidine | 138 | 31 |
| Omeprazole | Omeprazole | 130 | 44 |
| Ibuprofen | Ibuprofen | 129 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 120 | 42 |
| Lisinopril | Lisinopril | 114 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 35 |
| Simvastatin | Simvastatin | 93 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 35 |
| Carvedilol | Carvedilol | 89 | 31 |
| Nifedipine Er | Nifedipine | 88 | 29 |
| Meloxicam | Meloxicam | 86 | 23 |
| Naproxen | Naproxen | 82 | 23 |
| Baclofen | Baclofen | 80 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 77 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 21 |
| Furosemide | Furosemide | 66 | 23 |
| Promethazine Hcl | Promethazine Hcl | 62 | 16 |
| Myrbetriq | Mirabegron | 61 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | suppressed |
| Eliquis | Apixaban | 55 | 18 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 16 |
| Trazodone Hcl | Trazodone Hcl | 53 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 52 | 12 |
| Sertraline Hcl | Sertraline Hcl | 51 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 49 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | 15 |
| Jardiance | Empagliflozin | 44 | 16 |
| Valsartan | Valsartan | 44 | 11 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 43 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 18 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 41 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 11 |
| Azithromycin | Azithromycin | 39 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 12 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Celecoxib | Celecoxib | 38 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Levetiracetam | Levetiracetam | 34 | 11 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Ibu | Ibuprofen | 31 | 12 |
| Lidocaine | Lidocaine | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 23 | suppressed |
| Prednisone | Prednisone | 23 | 18 |
| Endocet | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 22 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $473.70 · 21 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AREXVY, BRIXADI, Cologuard Collection Kit, GVOKE HYPOPEN, JARDIANCE, Kerendia, MOUNJARO, REXULTI, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, Veozah, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error